Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBP.L Regulatory News (CBP)

  • There is currently no data for CBP

Form 8 (OPD) - Nucleus Financial Platforms Limited

9 Dec 2022 07:00

RNS Number : 1347J
Nucleus Financial Platforms Limited
09 December 2022
Β 

FORM 8 (OPD)

Β 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Full name of discloser:

Nucleus Financial Platforms Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Curtis Banks Group plc

(d) Is the discloser the offeror or the offeree?

Offeror

(e) Date position held:

The latest practicable date prior to the disclosure

8 December 2022

Β 

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

Β 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Β 

Class of relevant security:

Β 

ORDINARY SHARES OF 0.5p EACH

Β 

Β 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

-

Nil

-

(2) Cash-settled derivatives:

Β 

Nil

-

Nil

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

-

Nil

-

TOTAL:

Nil

-

Nil

-

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental FormΒ 8 (Open Positions).

Β 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

Β 

(b) Rights to subscribe for new securities

Β 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

Β 

Β 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

Interests in ordinary shares of 0.5 pence each in Curtis Banks Group plc held by persons acting in concert with Nucleus Financial Platforms Limited

Name

Number of ordinary shares

Percentage of issued share capital (per cent.)

N/A

N/A

N/A

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Β 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

Β 

Β 

(c) Attachments

Β 

Are any Supplemental Forms attached?

Β 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

Β 

Β 

Date of disclosure:

09 December 2022

Contact name:

Alice Dixie, Nucleus Financial Platforms Limited

Telephone number:

+44 (0)77 0255 5615

Β 

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

Β 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
FEETPBPTMTBMBMT
Date   Source Headline
8th Jun 20204:36 pmRNSPrice Monitoring Extension
4th Jun 20201:24 pmRNSResult of AGM
2nd Jun 20204:40 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:35 pmRNSPrice Monitoring Extension
29th May 20204:42 pmRNSSecond Price Monitoring Extn
29th May 20204:36 pmRNSPrice Monitoring Extension
1st May 20207:00 amRNSHolding(s) in Company
29th Apr 20205:02 pmRNSHolding(s) in Company
17th Apr 20204:40 pmRNSSecond Price Monitoring Extn
17th Apr 20204:35 pmRNSPrice Monitoring Extension
15th Apr 20204:40 pmRNSSecond Price Monitoring Extn
15th Apr 20204:35 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSPDMR share awards and Issue of options
18th Mar 20207:00 amRNSFinal Results
13th Mar 20204:40 pmRNSSecond Price Monitoring Extn
13th Mar 20204:35 pmRNSPrice Monitoring Extension
4th Feb 20207:00 amRNSNotice of Results
24th Sep 20193:18 pmRNSDirector/PDMR Shareholding
5th Sep 20197:00 amRNSInterim Results
7th Aug 201911:00 amRNSHolding(s) in Company
31st Jul 20197:00 amRNSNotice of Results
5th Jun 20197:00 amRNSAppointment of CFO
21st May 20195:09 pmRNSDirector/PDMR Shareholding
21st May 20194:45 pmRNSResult of AGM
30th Apr 20198:19 amRNSDirector/PDMR Shareholding
20th Mar 20197:00 amRNSFinal Results
31st Jan 20197:00 amRNSNotice of Results
22nd Jan 20198:30 amRNSNew Product Launch
18th Jan 20197:00 amRNSAppointment of Jane Ridgley to the Board
9th Jan 20197:00 amRNSDirectorate Change
11th Dec 20187:00 amRNSPurchase of Hargreave Hale SIPP book
9th Oct 20184:43 pmRNSDirector/PDMR Shareholding
8th Oct 201811:25 amRNSDirector/PDMR Shareholding
28th Sep 20189:08 amRNSHolding(s) in Company
6th Sep 20187:00 amRNSInterim Results
22nd Aug 20187:00 amRNSAppointment of Joint Broker
15th Jun 20189:15 amRNSNotice of Results
16th May 20183:30 pmRNSResult of AGM
30th Apr 201812:30 pmRNSTR-1: notification of major holdings
27th Apr 20185:15 pmRNSTR-1: notification of major holdings
26th Apr 20182:58 pmRNSResult of Placing
26th Apr 201811:20 amRNSProposed Placing
9th Apr 20189:00 amRNSJane Ridgley appointed Chief Operating Officer
27th Mar 20187:00 amRNSHolding(s) in Company
15th Mar 20187:00 amRNSFinal Results
16th Jan 20187:00 amRNSTrading Update
22nd Dec 20177:00 amRNSExercise of Options
18th Dec 20173:10 pmRNSUpdate on operating systems
16th Nov 20179:21 amRNSExercise of Options
10th Nov 201711:58 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.